T. Rowe Price holds 10.2% of Denali Therapeutics (DNLI) in 13G/A

Rhea-AI Filing Summary

Denali Therapeutics Inc Schedule 13G/A reports that T. Rowe Price Investment Management, Inc. beneficially owns 16,178,963 shares of common stock, representing 10.2% of the class as stated in the filing. The filing lists CUSIP 24823R105 and identifies the reporting person as a Maryland entity. The report shows 15,639,355 shares for which the filer has sole voting power and 16,178,963 shares for which it has sole dispositive power. The filing is signed by Ellen York, Vice President, dated 07/08/2026.

Insights

Institutional Ownership Analyst

Large passive stake disclosed by an institutional investor.

The filing states that T. Rowe Price Investment Management, Inc. beneficially holds 16,178,963 shares or 10.2% of Denali common stock as reported in the Schedule 13G/A.

This disclosure reflects a substantial passive or investment-management position; timing of accumulation and voting intentions beyond the sole voting/dispositive power numbers are not detailed in the excerpt.

Securities Compliance Specialist

Filing conforms to beneficial ownership disclosure norms for a large holder.

The Schedule 13G/A lists precise voting and dispositive-power counts: 15,639,355 sole voting power and 16,178,963 sole dispositive power. The report includes issuer address and CUSIP 24823R105.

Signatory and signature date are provided; the filing contains a denial of beneficial ownership language customary for managers reporting on behalf of clients.

Key Figures

Percent of class: 10.2% Shares beneficially owned: 16,178,963 shares Sole voting power: 15,639,355 shares +2 more

5 metrics

Percent of class 10.2% Beneficial ownership reported in Schedule 13G/A

Shares beneficially owned 16,178,963 shares Amount beneficially owned as stated in Item 4(a)

Sole voting power 15,639,355 shares Number with sole power to vote as stated in Item 4(c)(i)

Sole dispositive power 16,178,963 shares Number with sole power to dispose as stated in Item 4(c)(iii)

CUSIP 24823R105 Identifier for Denali common stock on the cover

Key Terms

Schedule 13G/A, Beneficially owned, Sole dispositive power

3 terms

Schedule 13G/A regulatory

"Item 1. (a) Name of issuer: DENALI THERAPEUTICS INC"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

Beneficially owned regulatory

"Item 4. (a) Amount beneficially owned: 16178963"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole dispositive power regulatory

"Item 4. (c)(iii) Sole power to dispose or to direct the disposition of: 16178963"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/08/2026 - 11:30 AM Accepted by SEC EDGAR 07/08/2026 - 11:30 AM Learn about SEC filing dates

FAQ

What stake does T. Rowe Price report in Denali Therapeutics (DNLI)?

The filing reports 16,178,963 shares, equal to 10.2% of Denali's common stock. The report lists sole voting power of 15,639,355 and sole dispositive power of 16,178,963.

What type of SEC filing did T. Rowe Price submit for DNLI?

T. Rowe Price submitted a Schedule 13G/A, an amendment to a beneficial ownership statement, disclosing holdings and voting/dispositive powers for Denali common stock with CUSIP 24823R105.

When was the Schedule 13G/A for DNLI signed?

The form is signed by Ellen York, Vice President, with a signature date of 07/08/2026, and the cover references 06/30/2026 as the reporting date context.

Does the filing state whether T. Rowe Price is the beneficial owner of the shares?

The filing includes a declaration denying beneficial ownership by T. Rowe Price Investment Management; it reports power figures while stating that beneficial ownership is expressly denied in the text.

What voting and dispositive powers are reported for DNLI shares?

The Schedule 13G/A lists 15,639,355 shares with sole voting power and 16,178,963 shares with sole dispositive power, with 0 shared voting or dispositive power reported.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

DENALI THERAPEUTICS INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

24823R105

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 24823R105

1

Names of Reporting Persons

T. Rowe Price Investment Management, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MARYLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 15,639,355.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 16,178,963.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

16,178,963.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

10.2 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: DENALI THERAPEUTICS INC
(b)	Address of issuer's principal executive offices: 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
Item 2.
(a)	Name of person filing: T. Rowe Price Investment Management, Inc.
(b)	Address or principal business office or, if none, residence: 1307 Point Street, Baltimore, MD 21231
(c)	Citizenship: Maryland
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 24823R105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 16178963
(b)	Percent of class: 10.2 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 15639355
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 16178963
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

T. Rowe Price Investment Management, Inc.

Signature:	Ellen York
Name/Title:	Vice President
Date:	07/08/2026